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ABSTRACT 
As from the last eras number of the revolution in the drug delivery technologies have been seen to attain the targeted drug delivery or site 
specific action of the drug. The prospects of the drug delivery by using biomimetic nanoparticles such as virosomes is an motivating research & 
development field as showing targeted action by fusion with the targeted action by fusion through target cell. It can be engaged as vehicle & 
vaccines furthermore victory of virosomal drug delivery depends on the method used to make the encapsulated bioactive materials, 
characterization & formulation of finished products. They are reconstituted viral envelopes that can be conveyance of different macromolecules 
as these are biocompatible, biodegradable, nonautoimmunogenic. Virosomes denotes such a unique system for presentation of antigen to 
immune system. Peptides, nucliecacid & medications such as antitoxins, anticancer agents &steroids can be encapsulated. This review focus on 
various aspects of Virosomes, such as Structure of Virosomes Component, Advantages, disadvantages, Method of preparation, Characterization, 
recent Patents and applications of Virosomes etc. 
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INTRODUCTION 
One of the causes of stoppage of the promising drug during 
development is failure to deliver to the target cell, tissue & 
organ 1, 2. The novel therapeutics includes the delivery that 
targets the drug to the particular cell & tissue by controlled 
release & receptor mediated uptake 3.  Furthermore the new 
generation of the therapeutics especially against cancer or 
neurogenerative disorders desires delivery system which 
target the drug to the host cell & tissue 4.Virosomal 
technology is developed in order to overcome the difficulty 
of incomplete delivery to the targetting cell, tissue & organs 
of the body 5.virosomes have become talentedcandidate for 
the targetting the drug & antigen delivery 6. As novel drug 
delivery technology should deliver improved bioavailability 
& should reduce the dose of the drug, during the clinical test 
several drugs fails due to the lack of delivery technology. The 
prospect of drug delivery & targetting using virosomes is an 
interesting field of research & development 7. Virosomal 
technology grants a novel sophisticated delivery system to 
meet the challenges of targeting to the cell & tissues; these 
are lipoidal biocarrier for site specific targetting 8.   Virosome 
is reconstituted viral envelope includes lipids membrane & 
viral spike glycoprotein but lacking of viral genetic materials, 
virosomes first primed by Almeida et al. by inserting purified 
influenza spike proteins into preformed liposomes. 
Thereafter a variety of viral envelops have been 
reconstituted including Sendai virus, Semliki forest virus & 
Sindbis virus. Virosomes shows viral envelop of glycoprotein 
& their native conformation stimulates humoral responses. 
Sendai virus virosomes generated by reconstitution of 
Sendai fusion protein9,10. In short Virosomes are regenerate 
empty influenza virus envelopes where infectious 
nucleocapside be substituted by compound of choice as they 
having pure fusion activity thus deliver the incorporated 
compounds to or inside the target cells,  in this compounds 
like drug, antigen, genes can be incorporated. One of major 
advantage which is the object of great interest of using 
virosomes as guards the incorporated compounds from 
proteolytic degradation & low pH within the endosomes as 
permits their content to remain intact while it reaches to the 
cytoplasm. Furthermore achievement of virosomal drug 
delivery depends on the technique used to prepare the 
encapsulated bioactive materials, characterisation & 
formulation of finished products. As virosomes are 
biodegradable, biocompatible, nontoxic & 
nonautoimmunogenic attempts were made to use them as a 
vaccines or adjuvants as well as delivery system for drug, 
nucleic acid, gene for therapeutic application 11. 
I) STRUCTURE OF VIROSOMES 
 Virosomes are semi-synthetic sphere-shaped or unilamellar 
complex derived from nucleic acid free viral particles, bilayer 
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vesicle mean diameter size ranges from 120-180 nm. 
Composed of lipid bilayer in which inserted viral 
glycoproteins are derivative from different enveloped virus. 
Virosomes are created by dissolving the envelop of a virus by 
detergent then viral membrane is reconstituted & produces 
virosome containing viral membrane proteins & lipids. 
Essentially Virosomes signifies reconstituted empty 
influenza virus envelops devoid of the nucleocapside with 
the genetic material of source virus. Influenza virus is most 
frequently used for virosomes production & genetic material 
of the source virus. The chief constitute of immune 
stimulating regenerate Influenza virosomes contain of 
naturally occurring Phosphatidyl choline (PC) & 
Phospholipids (PL), PC forms around 70% of the virosomal 
assembly & remaining 30% of membrane components are 
enclose phospholipids which originates from influenza virus 
containing the glycoproteins intercalated inside the 
phospholipid bilayer membrane & these glycoproteins are 
Neuraminidase (NA) & Haemagglutinin (HA) glycoproteins12. 
In distinction to liposomes, virosomes can be capable by 
intrinsic immunogenic properties functioning both the 
carrier & adjuvant that can be capable to deliver the antigen 
& stimulates immune cells simultaneously. HA & NA proteins 
of virosomesenables efficient vesicle uptake by later 
activation of cells of immune system. NA is a tetramer 
composed of 4 equal spherical subunits hydrophobically 
embedded in Immunostimulating Reconstituted Influenza 
Virosomes (IRIV) membrane by a central stalk & that readily 
intercalates into phospholipid membrane & involved in 
budding 13. NA present on IRIV’s exterior aids the action by 
the same mechanism through which it enhances influenza 
virus pathogenicity it catalyses the breakdown of N-
acetylneuraminic acid from bound sugar residue leads to 
decrease viscosity of host’s mucus permitting to the 
influenza virus an easier entree to epithelial cells, the same 
procedure leads to demolition of HA receptors within cell 
membrane to which viruses & IRIV’s binds. This allows virus 
particle to avoid aggregation as newly formed virus particle 
do not adhere to infected host cell membrane after budding. 
The mode of action of IRIV’s is dependent on the influenza 
haemagglutinin which is intercalated into the 
phospholipidbilayer &steadies the liposomes bases by 
preventing fusion with other liposomes. HA is major 
influenza antigen which is formed from two polypeptides 
HA1& HA2 which are involved in receptor binding & 
membrane fusion. 
HA1- Globular head contain a receptor site that has a high 
affinity for sialic acid present on antigen presenting cell 
(APC’s) surface like lymphocytes & macrophages. 
HA2- The fusion of IRIV’s with endosomal membrane is then 
mediated by HA2 polypeptide 14. 
 
Figure 1: Different component of Virosomes 
II) RATIONALE FOR USING AND DEVELOPING 
VIROSOMES 
 Solubilization of poorly water soluble drugs: diazepam, 
vitamin A, dexamethasone palmitate. 
 Site specific delivery to various organs: cytotoxic agents. 
 Potential for sustained release dosage forms – 
dexamethasone palmitate, barbiturates, physostigmine 
salicylate 15. 
III) ADVANTAGES OF VIROSOMES 
 This technology is approved by FDA for use in human & 
has proven to have safety profile. 
 Completely biodegradable, Biocompatible & nontoxic. 
 No risk of disease transmission, no auto immunogenicity. 
 Enables delivery of drug to conveyance into cytoplasm of 
target cell. 
 Defends drug against degradation. 
 Promotes combination movement in the endolysosomal 
pathway. 
 Controlled by either injection or nasally. 
 Allows tolerant specific modular vaccine regimes. 
 Up scaling according to standard procedure possible. 
 Virus like structures provides repetitive antigen 
presentation to B cells & mimics natural intracellular 
processing of the antigen that leads to stimulation of both 
arms of immune system, humoral & cellular immune 
responses. 
 The antigen is incompletely protected from extracellular 
degradation & the resulting depot effect greatly facilitates 
immune potentiation. 
 Extended uptake, distribution &elimination of drug in the 
body. 
 High quality & long lasting antibody responses. 
 Excellent safety profile. 
 Conformational stabilization of antigen. 
 They can be largely applied with almost all forms of 
drugs (Anticancer drugs, Antibiotics & fungicides) small 
organic molecules like proteins, peptides & nucleic acids. 
 Appropriate for elderly &infants 16. 
IV) DISADVANTAGES OF VIROSOMES 
 They might induce immune responses since they often 
have viral glycoprotein on the surface. 
 Rapid disintegration in the blood compartment is 
potential issue connected with virosomes, 
 Short shelf life. 
 Manufacturing problems. 
 Poor quality of raw materials. 
 Pay load is too slow. 
 Non availability of data related to chronic use of 
virosomes. 
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 Rapid disintegration can be overcome by growing the 
stability of virosomes or making virosomes reaches 
targetting sites inside a short time after administration 16. 
 Use of high quality products with improved purification 
protocols. 
 Quality control assay can be made by using sophisticated 
instruments & batch to batch variability can be checked. 
 Use of remote loading techniques to overcome payload 
problems. 
 Improvement in shelf life using appropriate 
cryoprotectants & lyoprotectants. 
 Scale up problems can be enhanced by selection of 
proper method of preparation & sterilization by 
autoclaving or membrane filtration coupled with aseptic 
& validated pyrogen removal Lal test. 
 By selecting drugs with narrow therapeutic index 17,18. 
V) METHOD OF PREPARATION OF VIROSOMES 
1. Selection of virus for virosomes- Virosomes are 
reconstructed viral envelope that can be derived from 
different virus. Influenza virus envelope is most 
commonly used to produce virosome but virosome can 
also be made from other unlike types of viruses also such 
as Sendai virus, Epstein-burr virus, HIV, sindbis, semliki-
forest virus, friend murine leukaemia virus, herpes 
simplex virus, Newcastle disease virus. 
2. Selection of antigen- Depending on the necessities 
antigens are selected. Antigens which are used like a 
bacteria parasite, carcinogenic cell, or whole cell is used 
as antigens. Cell components include RNA, DNA, or 
plasmid could also be used as antigen. This antigen is 
coupled to lipid anchor so antigen will be ready to load 
on virosomes. 
 Reconstitution of Virosomes- Virosome solubilised 
with detergent like octaglucoside, triton x-100, nonidert 
p-40 Due to solubilization with detergent internal viral 
protein and genetic material will residue then detergent 
is removed by dissimilar method such as dialysis and 
hydrobhobic resins from supernatant. By using 
ultracentrifugation process viral matrix protein and 
nucleicapsid is removed. Viral phospholipid (82%) and 
viral protein is recovered in supernatent.  Now antigen 
which is coupled to lipid anchor is mixed with polymer or 
surfactant solution and this solution is processed with 
virosome carrier so that antigen bound virosome is 
obtained 17,18. 
 
 
Figure 2: General method for preparation of virosomes 
 
VI) CHARACTERIZATION OF VIROSOMES 
1. Detection of protein- Virosomal preparation should 
result in a uniform protein to lipid ratio, presence of 
haemagglutinin protein on virosomes can be 
confirmed by Sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE). 
2. Fusion activity- Generally virosomes displays pH 
dependent film combination movement like local flu 
infection similar to native influenza virus, Fluorescent 
resonance energy transfer assay is used to visualized 
the virosomal fusion with artificial & biological target 
membrane fusion can be assessed in vitro with excimer 
virosomal combination with organic or counterfeit 
target film can be surveyed in vitro to measure 
utilizing pyrene-named lipid where decrease of surface 
density of pyrene- Phosphatidylcholine label on fusion 
with unlabelled membrane leads to decrease in 
fluorescence.   
3. Structure & size-Negative-stain electron microscopy 
generally used to determine ultrastructure and size of 
virosomes. The staining solution is of neutral pH, to 
avoid acid-induced conformational changes of HA. 
VII) MECHANISM OF ACTION OF VIROSOMES 
Virosomes operates together as a carrier & as the adjuvants 
with dissimilar types of functions for induction of immune 
responses, the carrier function involves the embedding of 
antigens into virosomes particles that gives the positive 
effect integration of antigen stability the antigen on surface 
of virosomes mimics the original pathogen & generates the 
antibodies. Induction of antigen on surface immunizes by 
creating the B cells such form complex are main focus for 
targetting immune cells which is important for induction of 
immunity. 
The adjuvant function relates to stimulation of immune 
properties of virosomes & components of immune system 
without causing nonspecific inflammation, adjuvant function 
is based on the presence of haemagglutinin pre-existing 
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antibodies against influenza bind to virosomes leads to rapid 
uptake & processing by Antigen presenting cells (APC). The 
natural function of antibody to bind virus & block infection, 
one of the factors to make virosomal particle attractive 
target for uptake & processing by immune cell, is the size & 
surface of virosomes which is important for initiating 
immune response.  APC activates pre-existing influenza 
specific helper T cell activated helper cells proliferates & 
secretes cytokines for stimulating immune cells 19. 
VIII) ROUTE OF ADMINISTRATION OF VIROSOMES 
They can be administered by ranges of routes including 
intravenous (IV), intramuscular (IM), subcutaneous (SC), 
intra-arterial & Inhalable delivery also by topically, orally & 
transdermally. Equipped virosomes suspended in saline 
buffer (135-150 mm NaCl), sterilized by conventional 
liposomal sterilization method such as membrane filtration. 
To mimic physiological status they need to contain auxiliary 
substances such as buffering agents & isotonicity regulating 
agent like Calcium chloride, Sodium lactate, Sodium acetate, 
Sodium chloride. The concentration of virosomes used in the 
vehicle ranges from 20-200 mg/ml, however it can 
optimized depending on the requirement for the purpose. 
The virosomes can be incorporated into implantable devices 
for long term therapy release. 
IX) EVALUATION OF VIROSOMES 
 Protein detection-Relatively uniform protein to lipid 
ratio is observed in prepared virosomes. To confirm the 
presence of HA protein, Sodium dodecyl sulfate- 
polyacrylamide gel electrophoresis (SDS- PAGE) method 
is used. 
 Surface charge- Free flow electrophoresis. 
 Structure & size- Negative stain electron microscopy 
with neutral staining agents is used, determined by 
photo correlation spectroscopy, transmission electron 
microscopy, dynamic light scattering, and gel 
permeation & gel exclusion techniques. 
 Lamellarity- It can be determined 13p-NMR, Freeze 
fracture electron microscopy. 
 Percent free drugs- It can be determined by mini 
column centrifugation, gel exclusion, radiolabel ling, 
protamine aggregation. 
 Phase behaviour- Differential scanning colorimetry, 
freeze fracture electron microscopy. 
 Drug release- Diffusion cell dialysis 
 Animal toxicity- It can be determined by monitoring 
history, pathology & survival rates. 
 Pyrogenicity- It can be determined by Rabbit fever test, 
Limulus ambeocyte lysate (LAL) test. 
 Surface chemical analysis- Static secondary ion mass 
spectrometry. 
X) PHARMACOKINETIC OF VIROSOMES 
Information regarding differences in the pharmacological 
effect of free drug & encapsulated drug can be given by the 
pharmacokinetic studies that help in dose designing; it can 
give the information regarding the absorption, distribution & 
degradation time course of retention, dissemination & 
debasement of the virosomal transport in-vivo. Effect of 
pharmacokinetic parameter on virosomes shown following 
outcomes- 
 Greater therapeutic index. 
 Greater concentration at targeted sites. 
 Protection of drug in plasma. 
 Decrease in toxicity& nonspecific reaction. 
 Reduction in nonspecific localization. 20. 
XI) APPLICATIONS OF VIROSOMES 
 Virosomes coupled to the antibody to improve the 
tissue specificity as antibody binds to the specific 
receptor a number of the virosomes based product 
have been approved by USFDA for human use. The 
main properties involves in the virosomal design is 
interaction between antigenic proteins of the virus & 
cellular receptors. The virosomal receptor interaction 
investigated for treating the parasitic disease, viral 
disease, neurological disease & other metabolic 
disorders. 
 Virosomes containing antibacterial, antimalarial, 
antifungal have shown effective Invitro & in vivo 
profile, the virosomes based sedates conveyance is in 
any case, quick, sheltered & viable rather than other 
related system. 
 Apart from this virosomes can also delivers proteins & 
peptides eg- gelonin subunit A of diphtheria toxin has 
been delivered to target cells by virosomes as well as 
ovalbumin. 
 Cancer treatment – Cancer is one of the major health 
issue worldwide still it remains great challenges as 
having potential application of NDDS in cancer therapy 
enabled the development of the novel therapeutic 
strategies.  
Virosomes also used in the oncology field as they can 
carry peptides to tumor associated antigens, peptides 
corresponding to Tumor Associated Antigens(TAA) as 
in case of peptides derived from the parathyroid 
hormone related protein (PTH-rp) or from 
recombinant protein such as Her-2/neu, Fab combined 
the anti-proliferate properties of monoclonal 
antibodies & cytotoxic effect of doxorubicin in vivo.
  
 Gene delivery- Haemagglutinin the membrane fusion 
protein of influenza virus known to mediate the low pH 
dependent fusion reaction between the viral envelop & 
limiting membrane of the endosomal cell compartment 
which follow cellular uptake of virus particle by 
receptor mediated endocytosis.  
 Malaria therapy- Virosomes shows good tolerability & 
highly specific immune responses it has been identified 
two peptides structures serving as antigens for malaria 
vaccines. The NPNA regions of circumsporozoite 
protein (CSP) loop I of domain III of merozoites apical 
membrane antigen-1 (AMA-1) that leads additional 
structural antigens that identified. 
 Immune stimulation – Virosomes provides pathogen- 
associated molecular pattern (PAMP) that that gives 
stimulatory signals to APC. 
 RNA/DNA delivery-Genetic materials encapsulated in 
virosomes are able to put adequate synthesis of newly 
induced expressed proteins overcoming lack of 
suitable delivery method for these molecules 
Intraperitoneal injection of SiRNA loaded virosomes 
resulted in delivery of nucleotide to peritoneal cell 21. 
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Table 1: First generation Virosomes22 
Products Indication Vaccine composition 
Epaxal ® 
 
Hepatitis A 
Adult 
A(H1N1) virosomes & inactivated Hepatitis A 
virus 
Inflexal ® 
Seasonal Influenza 
All age groups 
Virosomes from 3 Influenza strains A(H1N1), 
A(H3N3), B 
Nasalflu® 
Seasonal Influenza 
Intranasal application 
Virosomes from 3 Influenza strains 
A(H1N1), A(H3N2), B & HLT adjuvant 
Invivac ® Seasonal Influenza 
Virosomes from 3 Influenza strains 
A(H1N1), A(H3N2)B 
Epaxal ® Junior 
Hepatitis A 
child 
A(H1N1) virosomes & inactivated Hepatitis A 
virus 
 
Table 2: Second generation Virosomes(22) 
Disease, target, effector Antigen configuration Administration Route 
HIV 
Gp4 1 
antibody 
1 Peptide membrane-anchored 
Intramuscular prime & intranasal 
boost 
Malaria 
Plasmodium falciparum 
AMA-1 & CSP antibody 
2 peptides membrane-anchored Intramuscular 
Breast cancer 
Her2/neu 
antibody 
3 peptides membrane-anchored Intramuscular 
 
Table 3: Marketed Products of Virosomal drug delivery (22) 
S. No. Virosomal preparations Application 
A Virosomes antigen based products 
1 
1 Hepatitis A virus envelope proteins 
(EpaxalW) 
Hepatitis a 
2 Influenza virus (InflexalW V) Influenza 
B 
Virosomal antigen preparations 
under clinical trials 
1 
Diphtheria/tetanus toxoid virus envelope 
proteins 
Diphtheria, Tetanus 
2 
Peptidomimetic of loop I from domain  III of 
Plasmodium falciparum AMA-1 
Malaria 
3 PEV6 Breast cancer 
C Virosomal antigen preparations under pre-clinical trials 
1 Doxorubicin Cancer 
2 Doxorubicin Ovarian carcinoma 
3 L-myc antisense  ODNs Cancer 
4 DNA-encoded TAA Prostate Carcinoma 
5 DNA-encoded mumps antigen Mumps 
 
Table 4: Recent US Patents Of Virosomal Drug Delivery 22 
Sr.No. US Patent No. Title 
1 7576066 Nucleic acid compositions for stimulating immune responses 
2 7615227 Use of CpG oligodeoxynucleotides to induce angiogenesis 
3 7615377 Fluorescein-based metal sensors 
4 7615539 Nucleic acid-lipophilic conjugates 
5 7618641 Functionally reconstituted viral membranes containing adjuvant 
 
XII) CONCLUSION 
Virosomes represents an innovative novel drug delivery 
system for various biologically active molecules including 
nucleic acid & genes for different purpose, they are safe, 
completely biocompatible, and biodegradable their surface 
can be modified to facilitate targeted drug delivery. They can 
be delivered to the host body through altered routes like 
intranasal, intradermal, and intramuscular depending on the 
aim of immunization. Tissue targetting immune activation & 
potentiation are the chief advantages that making them 
efficient prophylactic & therapeutic agent, they can be 
exploited as carrier for targeted drugs & for 
immunomodulating molecules particularly in cancer 
therapy, Influenza virus considered as promising model for 
antigen & unrelated molecules delivery that could be helpful 
for development of new vaccines.Appication of Virosome in 
drug delivery  will bring a new prospective & also open a 
new era in the modern pharmaceutical field & also human 
life too. 
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